Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Prostate Cancer

A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Status: Enrolling
Updated:  2/29/2016
Michigan Institute of Urology, PC
mi
from
Utica, MI
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Status: Enrolling
Updated: 2/29/2016
Michigan Institute of Urology, PC
mi
from
Utica, MI
Click here to add this to my saved trials
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Status: Enrolling
Updated:  2/29/2016
Minnesota Oncology Hematology, P.A.
mi
from
Burnsville, MN
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Status: Enrolling
Updated: 2/29/2016
Minnesota Oncology Hematology, P.A.
mi
from
Burnsville, MN
Click here to add this to my saved trials
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Status: Enrolling
Updated:  2/29/2016
Minnesota Oncology Hematology , P.A.
mi
from
Coon Rapids, MN
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Status: Enrolling
Updated: 2/29/2016
Minnesota Oncology Hematology , P.A.
mi
from
Coon Rapids, MN
Click here to add this to my saved trials
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Status: Enrolling
Updated:  2/29/2016
Minnesota Oncology Hematology, PA
mi
from
Edina, MN
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Status: Enrolling
Updated: 2/29/2016
Minnesota Oncology Hematology, PA
mi
from
Edina, MN
Click here to add this to my saved trials
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Status: Enrolling
Updated:  2/29/2016
Minnesota Oncology Hematology, P.A.
mi
from
Fridley, MN
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Status: Enrolling
Updated: 2/29/2016
Minnesota Oncology Hematology, P.A.
mi
from
Fridley, MN
Click here to add this to my saved trials
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Status: Enrolling
Updated:  2/29/2016
Minnesota Oncology Hematology PA
mi
from
Maplewood, MN
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Status: Enrolling
Updated: 2/29/2016
Minnesota Oncology Hematology PA
mi
from
Maplewood, MN
Click here to add this to my saved trials
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Status: Enrolling
Updated:  2/29/2016
Minnesota Oncology and Hematology, PA
mi
from
Minneapolis, MN
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Status: Enrolling
Updated: 2/29/2016
Minnesota Oncology and Hematology, PA
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Status: Enrolling
Updated:  2/29/2016
Minnesota Oncology Hematology
mi
from
St. Paul, MN
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Status: Enrolling
Updated: 2/29/2016
Minnesota Oncology Hematology
mi
from
St. Paul, MN
Click here to add this to my saved trials
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Status: Enrolling
Updated:  2/29/2016
Minnesota Oncology Hematology, P.A.
mi
from
Woodbury, MN
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Status: Enrolling
Updated: 2/29/2016
Minnesota Oncology Hematology, P.A.
mi
from
Woodbury, MN
Click here to add this to my saved trials
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Status: Enrolling
Updated:  2/29/2016
Family Cancer Center Foundation, Inc.
mi
from
Southaven, MS
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Status: Enrolling
Updated: 2/29/2016
Family Cancer Center Foundation, Inc.
mi
from
Southaven, MS
Click here to add this to my saved trials
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Status: Enrolling
Updated:  2/29/2016
St. Louis Cancer Care, LLP
mi
from
Bridgeton, MO
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Status: Enrolling
Updated: 2/29/2016
St. Louis Cancer Care, LLP
mi
from
Bridgeton, MO
Click here to add this to my saved trials
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Status: Enrolling
Updated:  2/29/2016
Saint Luke's Cancer Institute at Saint Luke's Hospital
mi
from
Kansas City, MO
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Status: Enrolling
Updated: 2/29/2016
Saint Luke's Cancer Institute at Saint Luke's Hospital
mi
from
Kansas City, MO
Click here to add this to my saved trials
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Status: Enrolling
Updated:  2/29/2016
St. Louis Cancer Care, LLP
mi
from
St. Louis, MO
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Status: Enrolling
Updated: 2/29/2016
St. Louis Cancer Care, LLP
mi
from
St. Louis, MO
Click here to add this to my saved trials
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Status: Enrolling
Updated:  2/29/2016
Comprehensive Cancer Centers of Nevada
mi
from
Henderson, NV
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Status: Enrolling
Updated: 2/29/2016
Comprehensive Cancer Centers of Nevada
mi
from
Henderson, NV
Click here to add this to my saved trials
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Status: Enrolling
Updated:  2/29/2016
Oncology Hematology Specialists, P.A.
mi
from
Denville, NJ
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Status: Enrolling
Updated: 2/29/2016
Oncology Hematology Specialists, P.A.
mi
from
Denville, NJ
Click here to add this to my saved trials
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Status: Enrolling
Updated:  2/29/2016
NYU Langone Medical Center
mi
from
New York, NY
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Status: Enrolling
Updated: 2/29/2016
NYU Langone Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Status: Enrolling
Updated:  2/29/2016
Associated Medical Professionals of New York PLLC
mi
from
Syracuse, NY
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Status: Enrolling
Updated: 2/29/2016
Associated Medical Professionals of New York PLLC
mi
from
Syracuse, NY
Click here to add this to my saved trials
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Status: Enrolling
Updated:  2/29/2016
Raleigh Hematology Oncology Associates D.B.A., Cancer Centers of North Carolina
mi
from
Raleigh, NC
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Status: Enrolling
Updated: 2/29/2016
Raleigh Hematology Oncology Associates D.B.A., Cancer Centers of North Carolina
mi
from
Raleigh, NC
Click here to add this to my saved trials
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Status: Enrolling
Updated:  2/29/2016
Cancer Centers of Southwest Oklahoma
mi
from
Altus, OK
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Status: Enrolling
Updated: 2/29/2016
Cancer Centers of Southwest Oklahoma
mi
from
Altus, OK
Click here to add this to my saved trials
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Status: Enrolling
Updated:  2/29/2016
Cancer Centers of Southwest Oklahoma
mi
from
Duncan, OK
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Status: Enrolling
Updated: 2/29/2016
Cancer Centers of Southwest Oklahoma
mi
from
Duncan, OK
Click here to add this to my saved trials
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Status: Enrolling
Updated:  2/29/2016
Northwest Cancer Specialists, PC
mi
from
Tualatin, OR
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Status: Enrolling
Updated: 2/29/2016
Northwest Cancer Specialists, PC
mi
from
Tualatin, OR
Click here to add this to my saved trials
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Status: Enrolling
Updated:  2/29/2016
Charleston Hematology/Oncology Associates, Pa
mi
from
Charleston, SC
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Status: Enrolling
Updated: 2/29/2016
Charleston Hematology/Oncology Associates, Pa
mi
from
Charleston, SC
Click here to add this to my saved trials
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Status: Enrolling
Updated:  2/29/2016
Family Cancer Center Foundation, Inc.
mi
from
Bartlett, TN
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Status: Enrolling
Updated: 2/29/2016
Family Cancer Center Foundation, Inc.
mi
from
Bartlett, TN
Click here to add this to my saved trials
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Status: Enrolling
Updated:  2/29/2016
Texas Oncology, PA - Austin North
mi
from
Austin, TX
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Status: Enrolling
Updated: 2/29/2016
Texas Oncology, PA - Austin North
mi
from
Austin, TX
Click here to add this to my saved trials
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Status: Enrolling
Updated:  2/29/2016
Texas Oncology-Dallas Presbyterian Hospital
mi
from
Dallas, TX
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Status: Enrolling
Updated: 2/29/2016
Texas Oncology-Dallas Presbyterian Hospital
mi
from
Dallas, TX
Click here to add this to my saved trials
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Status: Enrolling
Updated:  2/29/2016
Univ of Washington
mi
from
Seattle, WA
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Status: Enrolling
Updated: 2/29/2016
Univ of Washington
mi
from
Seattle, WA
Click here to add this to my saved trials
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Status: Enrolling
Updated:  2/29/2016
Northwest Cancer Specialists
mi
from
Vancouver, WA
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Status: Enrolling
Updated: 2/29/2016
Northwest Cancer Specialists
mi
from
Vancouver, WA
Click here to add this to my saved trials
Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer (CRPC) Patients Previously Treated on Dendreon Study P-11 (NCT00779402)
An Open-Label Multicenter Study of Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer Patients Previously Treated With Sipuleucel-T on Dendreon Study P-11 (NCT00779402)
Status: Enrolling
Updated:  2/29/2016
Oregon Health and Science University
mi
from
Portland, OR
Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer (CRPC) Patients Previously Treated on Dendreon Study P-11 (NCT00779402)
An Open-Label Multicenter Study of Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer Patients Previously Treated With Sipuleucel-T on Dendreon Study P-11 (NCT00779402)
Status: Enrolling
Updated: 2/29/2016
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer (CRPC) Patients Previously Treated on Dendreon Study P-11 (NCT00779402)
An Open-Label Multicenter Study of Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer Patients Previously Treated With Sipuleucel-T on Dendreon Study P-11 (NCT00779402)
Status: Enrolling
Updated:  2/29/2016
Virginia Mason Medical Center
mi
from
Seattle, WA
Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer (CRPC) Patients Previously Treated on Dendreon Study P-11 (NCT00779402)
An Open-Label Multicenter Study of Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer Patients Previously Treated With Sipuleucel-T on Dendreon Study P-11 (NCT00779402)
Status: Enrolling
Updated: 2/29/2016
Virginia Mason Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer (CRPC) Patients Previously Treated on Dendreon Study P-11 (NCT00779402)
An Open-Label Multicenter Study of Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer Patients Previously Treated With Sipuleucel-T on Dendreon Study P-11 (NCT00779402)
Status: Enrolling
Updated:  2/29/2016
Virginia Mason Hospital
mi
from
Seattle, WA
Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer (CRPC) Patients Previously Treated on Dendreon Study P-11 (NCT00779402)
An Open-Label Multicenter Study of Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer Patients Previously Treated With Sipuleucel-T on Dendreon Study P-11 (NCT00779402)
Status: Enrolling
Updated: 2/29/2016
Virginia Mason Hospital
mi
from
Seattle, WA
Click here to add this to my saved trials
Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer (CRPC) Patients Previously Treated on Dendreon Study P-11 (NCT00779402)
An Open-Label Multicenter Study of Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer Patients Previously Treated With Sipuleucel-T on Dendreon Study P-11 (NCT00779402)
Status: Enrolling
Updated:  2/29/2016
Orange County Urology Associates
mi
from
Laguna Hills, CA
Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer (CRPC) Patients Previously Treated on Dendreon Study P-11 (NCT00779402)
An Open-Label Multicenter Study of Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer Patients Previously Treated With Sipuleucel-T on Dendreon Study P-11 (NCT00779402)
Status: Enrolling
Updated: 2/29/2016
Orange County Urology Associates
mi
from
Laguna Hills, CA
Click here to add this to my saved trials
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
A Randomized, Phase 2, Open-label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
Status: Enrolling
Updated:  2/29/2016
Mayo Clinic Hospital
mi
from
Phoenix, AZ
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
A Randomized, Phase 2, Open-label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
Status: Enrolling
Updated: 2/29/2016
Mayo Clinic Hospital
mi
from
Phoenix, AZ
Click here to add this to my saved trials
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
A Randomized, Phase 2, Open-label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
Status: Enrolling
Updated:  2/29/2016
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
A Randomized, Phase 2, Open-label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
Status: Enrolling
Updated: 2/29/2016
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
A Randomized, Phase 2, Open-label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
Status: Enrolling
Updated:  2/29/2016
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
A Randomized, Phase 2, Open-label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
Status: Enrolling
Updated: 2/29/2016
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
A Randomized, Phase 2, Open-label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
Status: Enrolling
Updated:  2/29/2016
Genesis Research
mi
from
San Diego, CA
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
A Randomized, Phase 2, Open-label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
Status: Enrolling
Updated: 2/29/2016
Genesis Research
mi
from
San Diego, CA
Click here to add this to my saved trials
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
A Randomized, Phase 2, Open-label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
Status: Enrolling
Updated:  2/29/2016
Stanford University Hospital
mi
from
Stanford, CA
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
A Randomized, Phase 2, Open-label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
Status: Enrolling
Updated: 2/29/2016
Stanford University Hospital
mi
from
Stanford, CA
Click here to add this to my saved trials
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
A Randomized, Phase 2, Open-label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
Status: Enrolling
Updated:  2/29/2016
University of Colorado Anschutz Cancer Pavilion
mi
from
Aurora, CO
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
A Randomized, Phase 2, Open-label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
Status: Enrolling
Updated: 2/29/2016
University of Colorado Anschutz Cancer Pavilion
mi
from
Aurora, CO
Click here to add this to my saved trials
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
A Randomized, Phase 2, Open-label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
Status: Enrolling
Updated:  2/29/2016
Urology Center of Colorado
mi
from
Denver, CO
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
A Randomized, Phase 2, Open-label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
Status: Enrolling
Updated: 2/29/2016
Urology Center of Colorado
mi
from
Denver, CO
Click here to add this to my saved trials
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
A Randomized, Phase 2, Open-label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
Status: Enrolling
Updated:  2/29/2016
Neag Comprehensive Cancer Center/University of Connecticut Health Center
mi
from
Farmington, CT
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
A Randomized, Phase 2, Open-label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
Status: Enrolling
Updated: 2/29/2016
Neag Comprehensive Cancer Center/University of Connecticut Health Center
mi
from
Farmington, CT
Click here to add this to my saved trials
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
A Randomized, Phase 2, Open-label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
Status: Enrolling
Updated:  2/29/2016
Yale University School of Medicine
mi
from
New Haven, CT
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
A Randomized, Phase 2, Open-label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
Status: Enrolling
Updated: 2/29/2016
Yale University School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
A Randomized, Phase 2, Open-label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
Status: Enrolling
Updated:  2/29/2016
Urological Research Network
mi
from
Hialeah, FL
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
A Randomized, Phase 2, Open-label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
Status: Enrolling
Updated: 2/29/2016
Urological Research Network
mi
from
Hialeah, FL
Click here to add this to my saved trials
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
A Randomized, Phase 2, Open-label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
Status: Enrolling
Updated:  2/29/2016
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
A Randomized, Phase 2, Open-label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
Status: Enrolling
Updated: 2/29/2016
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
A Randomized, Phase 2, Open-label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
Status: Enrolling
Updated:  2/29/2016
Emory Department of Urology, The Emory Clinic Inc, Emory University Hospital
mi
from
Atlanta, GA
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
A Randomized, Phase 2, Open-label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
Status: Enrolling
Updated: 2/29/2016
Emory Department of Urology, The Emory Clinic Inc, Emory University Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
A Randomized, Phase 2, Open-label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
Status: Enrolling
Updated:  2/29/2016
American Red Cross
mi
from
Atlanta, GA
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
A Randomized, Phase 2, Open-label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
Status: Enrolling
Updated: 2/29/2016
American Red Cross
mi
from
Atlanta, GA
Click here to add this to my saved trials
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
A Randomized, Phase 2, Open-label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
Status: Enrolling
Updated:  2/29/2016
University of Chicago Medical Center
mi
from
Chicago, IL
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
A Randomized, Phase 2, Open-label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
Status: Enrolling
Updated: 2/29/2016
University of Chicago Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
A Randomized, Phase 2, Open-label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
Status: Enrolling
Updated:  2/29/2016
Indiana University
mi
from
Indianapolis, IN
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
A Randomized, Phase 2, Open-label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
Status: Enrolling
Updated: 2/29/2016
Indiana University
mi
from
Indianapolis, IN
Click here to add this to my saved trials
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
A Randomized, Phase 2, Open-label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
Status: Enrolling
Updated:  2/29/2016
Kansas City Urology Care, PA
mi
from
Overland Park, KA
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
A Randomized, Phase 2, Open-label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
Status: Enrolling
Updated: 2/29/2016
Kansas City Urology Care, PA
mi
from
Overland Park, KA
Click here to add this to my saved trials
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
A Randomized, Phase 2, Open-label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
Status: Enrolling
Updated:  2/29/2016
University of Kansas Cancer Center
mi
from
Westwood, KA
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
A Randomized, Phase 2, Open-label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
Status: Enrolling
Updated: 2/29/2016
University of Kansas Cancer Center
mi
from
Westwood, KA
Click here to add this to my saved trials
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
A Randomized, Phase 2, Open-label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
Status: Enrolling
Updated:  2/29/2016
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
A Randomized, Phase 2, Open-label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
Status: Enrolling
Updated: 2/29/2016
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
A Randomized, Phase 2, Open-label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
Status: Enrolling
Updated:  2/29/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
A Randomized, Phase 2, Open-label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
Status: Enrolling
Updated: 2/29/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials